Home » Sunesis, MMRC to Study Multiple Myeloma Treatment
Sunesis, MMRC to Study Multiple Myeloma Treatment
Sunesis Pharmaceuticals and the Multiple Myeloma Research Consortium (MMRC) will evaluate Sunesis’ SNS-032 as a potential treatment of multiple myeloma.
The collaboration will examine the preclinical activity of SNS-032 in multiple myeloma-relevant models and primary disease tissue.
SNS-032 is a potent, selective inhibitor of cyclin-dependent kinases 2, 7 and 9, which inhibits both cell cycle progression and transcription, Sunesis said.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May